Roquefort Therapeutics plc
ROQ.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £5,248 | £9,363 | £6,856 | £2,594 |
| - Cash | £337 | £537 | £2,323 | £900 |
| + Debt | £400 | £0 | £0 | £0 |
| Enterprise Value | £5,311 | £8,826 | £4,533 | £1,694 |
| Revenue | £0 | £200 | £0 | £1 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | -£16 | £200 | £0 | -£9 |
| % Margin | – | 100% | – | -1,300.4% |
| EBITDA | -£1,112 | -£1,928 | £0 | -£352 |
| % Margin | – | -964.2% | – | -49,012.9% |
| Net Income | -£972 | -£1,745 | -£1,615 | -£917 |
| % Margin | – | -872.3% | – | -127,598.5% |
| EPS Diluted | -0.008 | -0.014 | -0.016 | -0.037 |
| % Growth | 44.4% | 13.5% | 58% | – |
| Operating Cash Flow | -£784 | -£1,734 | -£1,577 | -£2,623 |
| Capital Expenditures | £0 | -£54 | -£0 | -£0 |
| Free Cash Flow | -£784 | -£1,788 | -£1,577 | -£2,623 |